{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:08:43Z","timestamp":1773029323389,"version":"3.50.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004160","name":"Mazandaran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>New therapeutic options are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19). Repurposing existing pharmaceuticals provides an immediate treatment opportunity. We assessed the efficacy of sofosbuvir and daclatasvir with ribavirin for treating patients with COVID-19.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a single-centre, randomized controlled trial in adults with moderate COVID-19 admitted to the Ghaem Shahr Razi Hospital in Mazandaran Province, Iran. Patients were randomly assigned to 400\u2009mg sofosbuvir, 60\u2009mg daclatasvir and 1200\u2009mg ribavirin (intervention group) or to standard care (control group). The primary endpoint of this study was length of hospital stay. This study is registered by IRCT.ir under the ID: IRCT20200328046886N1.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between 20 March 2020 and 8 April 2020, 48 patients were recruited; 24 patients were randomly assigned to the intervention group and 24 to the control group. The median duration of hospital stay was 6\u2009days in both groups (P\u2009=\u20090.398). The number of ICU admissions in the sofosbuvir\/daclatasvir\/ribavirin group was not significantly lower than the control group (0 versus 4, P\u2009=\u20090.109). There was no difference in the number of deaths between the groups (0 versus 3, P\u2009=\u20090.234). The cumulative incidence of recovery was higher in the sofosbuvir\/daclatasvir\/ribavirin arm (Gray\u2019s P\u2009=\u20090.033).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This randomized trial was too small to make definitive conclusions. There were trends in favour of the sofosbuvir\/daclatasvir\/ribavirin arm for recovery and lower death rates. However, there was an imbalance in the baseline characteristics between the arms. Larger randomized trials should be conducted to investigate this treatment further.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkaa332","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T03:20:18Z","timestamp":1594178418000},"page":"3373-3378","source":"Crossref","is-referenced-by-count":71,"title":["Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial"],"prefix":"10.1093","volume":"75","author":[{"given":"Hamideh","family":"Abbaspour Kasgari","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siavash","family":"Moradi","sequence":"additional","affiliation":[{"name":"Education Development Center, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5313-1133","authenticated-orcid":false,"given":"Amir Mohammad","family":"Shabani","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhang","family":"Babamahmoodi","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Reza","family":"Davoudi Badabi","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotfollah","family":"Davoudi","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Alikhani","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akbar","family":"Hedayatizadeh Omran","sequence":"additional","affiliation":[{"name":"Gastrointestinal Cancer Research Center, Cancer Research Institute, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Saeedi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Research Center, Hemoglobinopathy Research Institute, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8088-6723","authenticated-orcid":false,"given":"Shahin","family":"Merat","sequence":"additional","affiliation":[{"name":"Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Wentzel","sequence":"additional","affiliation":[{"name":"School of Public Health, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Garratt","sequence":"additional","affiliation":[{"name":"Cardiff and Vale University Health Board, Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Levi","sequence":"additional","affiliation":[{"name":"Accident and Emergency Department, Homerton University Hospital NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryony","family":"Simmons","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafez","family":"Tirgar Fakheri","sequence":"additional","affiliation":[{"name":"Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,8,19]]},"reference":[{"key":"2020101604551679500_dkaa332-B1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"2020101604551679500_dkaa332-B2","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3390\/jcm9040967","article-title":"A systematic review of COVID-19 epidemiology based on current evidence","volume":"9","author":"Park","year":"2020","journal-title":"J Clin Med"},{"key":"2020101604551679500_dkaa332-B3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1017\/ice.2020.86","article-title":"Coronavirus disease 2019 (COVID-19) outbreak in Iran: actions and problems","volume":"41","author":"Abdi","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020101604551679500_dkaa332-B4"},{"key":"2020101604551679500_dkaa332-B5","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N Engl J Med"},{"key":"2020101604551679500_dkaa332-B6","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"2020101604551679500_dkaa332-B7","doi-asserted-by":"crossref","first-page":"m1849","DOI":"10.1136\/bmj.m1849","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"BMJ"},{"key":"2020101604551679500_dkaa332-B8","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"2020101604551679500_dkaa332-B9","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"2020101604551679500_dkaa332-B10","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19\u2014preliminary report","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"2020101604551679500_dkaa332-B11","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"2020101604551679500_dkaa332-B12","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/cid\/ciz628","article-title":"SD1000: high sustained viral response rate in 1361 patients with hepatitis C genotypes 1, 2, 3, and 4 using a low-cost, fixed-dose combination tablet of generic sofosbuvir and daclatasvir: a multicenter, Phase III clinical trial","volume":"70","author":"Merat","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2020101604551679500_dkaa332-B13","year":"2015"},{"key":"2020101604551679500_dkaa332-B14","doi-asserted-by":"crossref","first-page":"e0007072","DOI":"10.1371\/journal.pntd.0007072","article-title":"Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo","volume":"13","author":"de Freitas","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2020101604551679500_dkaa332-B15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.antiviral.2016.11.023","article-title":"The FDA-approved drug sofosbuvir inhibits Zika virus infection","volume":"137","author":"Bullard-Feibelman","year":"2017","journal-title":"Antiviral Res"},{"key":"2020101604551679500_dkaa332-B16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/cbdd.13091","article-title":"Sofosbuvir as treatment against dengue?","volume":"91","author":"Gan","year":"2018","journal-title":"Chem Biol Drug Des"},{"key":"2020101604551679500_dkaa332-B17","doi-asserted-by":"crossref","first-page":"e01389","DOI":"10.1128\/AAC.01389-18","article-title":"Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication","volume":"63","author":"Ferreira","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101604551679500_dkaa332-B18","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J Med Virol"},{"key":"2020101604551679500_dkaa332-B19","article-title":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase","author":"Chien","year":"2020","journal-title":"bioRxiv"},{"key":"2020101604551679500_dkaa332-B20","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/jmv.24736","article-title":"Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses","volume":"89","author":"Elfiky","year":"2017","journal-title":"J Med Virol"},{"key":"2020101604551679500_dkaa332-B21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12967-020-02430-9","article-title":"Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)","volume":"18","author":"Kim","year":"2020","journal-title":"J Transl Med"},{"key":"2020101604551679500_dkaa332-B22","doi-asserted-by":"crossref","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci"},{"key":"2020101604551679500_dkaa332-B23","first-page":"44","article-title":"In silico study of various antiviral drugs, vitamins, and natural substances as potential binding compounds with SARS-CoV-2 main protease","volume":"1","author":"Alabboud","year":"2020","journal-title":"DLS"},{"key":"2020101604551679500_dkaa332-B24","article-title":"Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir","author":"Lo","year":"2020","journal-title":"bioRxiv"},{"key":"2020101604551679500_dkaa332-B25","article-title":"The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2","author":"Sacramento","year":"2020","journal-title":"bioRxiv"},{"key":"2020101604551679500_dkaa332-B26","article-title":"Evaluation of 19 antiviral drugs against SARS-CoV-2 infection","author":"Liu","year":"2020","journal-title":"bioRxiv"},{"key":"2020101604551679500_dkaa332-B27","year":"2015"},{"key":"2020101604551679500_dkaa332-B28","year":"2015"},{"key":"2020101604551679500_dkaa332-B29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S2055-6640(20)30018-2","article-title":"Minimum costs to manufacture new treatments for COVID-19","volume":"6","author":"Hill","year":"2020","journal-title":"J Virus Erad"},{"key":"2020101604551679500_dkaa332-B30","doi-asserted-by":"crossref","first-page":"e102324","DOI":"10.5812\/iranjradiol.102324","article-title":"Radiologic management of COVID-19: preliminary experience of the Iranian Society of Radiology COVID-19 Consultant Group (ISRCC)","volume":"17","author":"Mahdavi","year":"2020","journal-title":"Iran J Radiol"},{"key":"2020101604551679500_dkaa332-B31","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon \u03b2-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/11\/3373\/33893311\/dkaa332.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/11\/3373\/33893311\/dkaa332.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T17:40:32Z","timestamp":1667324432000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/11\/3373\/5889947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,19]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,8,19]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa332","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,8,19]]}}}